HIV - Change of guard

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-12-22

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The HIV market generated $7.4 billion of sales in 2005 and experienced a CAGR of 13.3% from 2001-2005, making it one of the fastest growing infectious diseases sub sectors. Despite the antiretroviral market's relative immaturity, many older flagship products such as Combivir are expected to lose patent protection before 2015.


Scope

  • In-depth analysis of the current HIV market across the major Western markets (US, France, Germany, Italy, Spain, UK)
  • Thorough assessment of underlying commercial and clinical influencing factors shaping the antiretroviral market
  • Detailed sales forecasts for the three major antiretroviral classes, molecules and brands in each of the six major markets
  • Case study analysis of the competitive environment and critical success factors in the Protease Inhibitor class


    • Report Highlights
    By 2015 the global antibacterial market is forecast to be valued at more than $10 billion with a modest CAGR of 4.1%. The main contributor to growth will be the new drug classes such as integrase- and entry inhibitors.

    Since the advent of HAART, HIV has turned into a chronic disease with an average life expectancy similar to that of Type 2 diabetes, emphasizing the importance of side effect profiles associated with long-term use.

    The launch of several new products from new classes such as integrase inhibitors, CCR5 inhibitors from 2007, and recently launched PIs, will cause the salvage market to decline. Despite proven synergy between Fuzeon and the new drugs, use of the former is predicted to decline.


    Reasons to Purchase

  • Understand the constantly evolving market dynamics of antiretroviral (ARV) drugs
  • Explore the impact of pending patent expiries and generic incursion on the ARV market, including product-specific case studies
  • Obtain full global, country, class and product-specific forecasts of currently marketed and pipeline ARVs from 2005 to 2015.

    • Table of Contents

    Other users found this report page using the following search terms: hiv ccr5 integrase invirase sales reyataz patent expiry

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.